The global inflammatory bowel disease treatment market size was valued at USD 15.9 billion in 2018 and is expected to register a CAGR of 4.4% from 2018 to 2026. Presence of strong pipeline products for the treatment of inflammatory bowel disease (IBD) is anticipated to drive the market over the forecast period.
Major players such as Shire; AbbViee Inc.; Celgene, Eli Lilly and Company; Pfizer Inc.; and Gilead Sciences are involved in research and development to introduce and commercialize better versions of existing products. Pipeline products such as Upadacitinib, Ozanimod, and Risankizumab are estimated to have better mechanism of action and efficacy.
Emergence of biosimilars is also one of the major factors governing the overall market. Biosimilars are expected to be less costly than biologics, making them more accessible in developing countries. The expected patent expiration of some of the drugs is one of the factors responsible for the launch of new biosimilars.
For instance, in 2016, the U.S. FDA approved a biosimilar Inflectra, which is similar to Remicade with lower competitive pricing. Remicade, a biologic drug manufactured by Janssen Non-surgical and approved in 1998, is majorly used for the treatment of Crohn’s disease and ulcerative colitis.
Crohn’s disease and ulcerative colitis are two major types of IBDs. Crohn’s disease was the largest segment in 2018 due to increasing prevalence of the condition. According to an article published in the Jobson Medical Information LLC, in 2018, the incidence of CD was found to be around 3.1 to 14.6 cases per 100,000 person every year and the prevalence was approximately 201 cases per 100,000 adults in U.S.
Ulcerative colitis is estimated to be the fastest growing segment over the forecast year owing to presence of strong pipeline products for its treatment. Moreover, increasing involvement of key players in product development related in the field is anticipated to drive the segment. In March 2019, Johnson & Johnson Services Inc. announced new data from its Phase III UNIFI study showing positive results of STELARA in adults suffering from moderate to severe ulcerative colitis.
On the basis of route of administration, the IBD treatment market is segmented into oral route and injectables. Injectables are considered to be the largest segment owing to their efficacy. In addition, emergence of biosimilars such as Inflectra is expected to fuel segment growth. This segment is further divided into IL inhibitors, TNF inhibitors, and anti-integrin. TNF-inhibitors was the largest sub-segment in 2018.
Oral route is estimated to be the fastest growing segment over the forecast period due to presence of strong pipeline products. The oral segment is further segmented into ASAs, corticosteroids, and JAK inhibitors. ASAs dominated the market in 2018 and JAK inhibitors are estimated to be the fastest growing sub-segment over the forecast period.
Based on distribution channel, the inflammatory bowel disease (IBD) treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment, which includes both in-patient and out-patient, dominated the market with a share of 36.6% in 2018. Increasing prevalence of Crohn’s disease and ulcerative colitis has led to an increase in the total number of hospitalizations worldwide.
Online pharmacy is estimated to be the fastest growing segment over the forecast period. The trend of online purchasing and the demand for it is growing due to comfort, flexibility, and convenience, which is increasing the revenue generated by this segment. Moreover, online shopping offers various discounts, which additionally benefit customers. These factors are expected to boost the demand for online pharmacies over the forecast period.
North America led the market in 2018 owing to presence of key companies and well-established healthcare infrastructure. The region is projected to maintain its dominance during the forecast years on account of increasing geriatric population base and prevalence of ulcerative colitis and Crohn’s disease.
According to an article published in the Jobson Medical Information LLC, in 2018, the incidence of CD was found to be around 3.1 to 14.6 cases per 100,000 person every year and the prevalence was approximately 201 cases per 100,000 adults in U.S. Asia Pacific is estimated to be the fastest growing regional segment over the forecast period due to rising product approvals.
Some of the key companies in this market are Johnson & Johnson Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Celltrion Healthcare Co., Ltd.; CELGENE CORPORATION; COSMO PHARMACEUTICALS; Innovate Biopharmaceuticals; UCB S.A.; and Gilead Sciences. They are majorly focused on regional expansion, strategic agreements, and research and development of novel products.
For instance, in 2017, Janssen Biotech, Inc. entered into a strategic agreement with Protagonist Therapeutics, Inc. to develop, manufacture, and market PTG-200, an oral IL 23 receptor for the treatment of inflammatory bowel disease. In 2018, Pfizer Inc. received marketing authorization of XELJANZ from the European Union for the treatment of moderate to severe ulcerative colitis.
Report Attribute |
Details |
Market size value in 2020 |
USD 17.2 billion |
Revenue forecast in 2026 |
USD 22.4 billion |
Growth Rate |
CAGR of 4.4% from 2019 to 2026 |
Base year for estimation |
2018 |
Historical data |
2014 - 2017 |
Forecast period |
2019 - 2026 |
Quantitative units |
Revenue in USD Million and CAGR from 2019 to 2026 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered |
Type, route of administration, distribution, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; Spain; France; Italy; China; Japan; India; South Korea; Singapore; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Johnson & Johnson Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Celltrion Healthcare Co., Ltd.; CELGENE CORPORATION; COSMO PHARMACEUTICALS; Innovate Biopharmaceuticals; UCB S.A.; Gilead Sciences |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global inflammatory bowel disease treatment market report on the basis of type, route of administration, distribution, and region:
Type Outlook (Revenue, USD Million, 2014 - 2026)
Crohn’s disease
Ulcerative colitis
Route of Administration Outlook (Revenue, USD Million, 2014 - 2026)
Injectables
TNF-inhibitors
IL inhibitors
Anti-integrin
Others
Oral
ASAs
Corticosteroids
JAK inhibitors
Others
Distribution Channel Outlook (Revenue, USD Million, 2014 - 2026)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Regional Outlook (Revenue, USD Million, 2014 - 2026)
North America
U.S.
Canada
Europe
U.K.
Germany
Spain
France
Italy
Asia Pacific
China
Japan
India
South Korea
Singapore
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global inflammatory bowel disease treatment market size was estimated at USD 16.7 billion in 2019 and is expected to reach USD 17.2 billion in 2020.
b. The global inflammatory bowel disease treatment market is expected to grow at a compound annual growth rate of 4.4% from 2019 to 2026 to reach USD 22.3 billion by 2026.
b. Crohn's disease dominated the inflammatory bowel disease treatment market with a share of 59.9% in 2019. This is attributable to the increasing prevalence of the condition. Moreover, the increasing involvement of key players in product development is anticipated to drive segment growth.
b. Some key players operating in the inflammatory bowel disease treatment market include Johnson & Johnson Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Celltrion Healthcare Co., Ltd.; CELGENE CORPORATION; COSMO PHARMACEUTICALS; Innovate Biopharmaceuticals; UCB S.A.; and Gilead Sciences.
b. Key factors that are driving the inflammatory bowel disease treatment market growth include the presence of strong pipeline products and the emergence of biosimilars.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.